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Bosniak category III or IV cystic lesion
treatment
Heatsink effect
A B S T R A C T
Purpose of the study: The aim of the study was to assess the efﬁcacy, safety and effectiveness of percutaneous
image-guided microwave ablation (MWA) in Bosniak category III or IV cystic renal lesions after 24 months
follow-up duration.
Methods : Between May 2008 and December 2012, computed tomography (CT)- or ultrasound (US)-guided
MWAwas performed in 6 patientswith 7 cystic renal lesions (range 13.8–27mm,mean 17.02mm, SD 8.5mm)
Bosniak catgegory III or IV. The number of treatment sessions, treatment results, lesion size changes and
complications were evaluated. Technical success (TS), technical effectiveness (TE), local tumor progression
rate (LTPR), cancer-speciﬁc survival rate (CSSR) and overall survival rate (OSR) were computed.
Main ﬁndings: TS was 100% (7/7) and TE was 100%; LTPR was 0%; CSSR and OSR were 100%. No major
complications were observed.
Conclusion: Our preliminary experience with MWA shows a potential role for US/CT-guided percutaneous
MWA in treating Bosniak category III or IV cystic renal lesions, as a safe approach to treat selected patients
not suitable for surgery.
© 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Bosniak III or IV cystic lesions may carry a particular risk for malig-
nancy even if some of these lesions (particularly Bosniak III lesions)
are proven to be benign after biopsy or surgery. 1–3 Warren et al.
summarized data obtained from several studies correlating pathology
with Bosniak category, reporting the risks of malignancy for Bosniak
III and IV lesions to be 16–100% and 90–100%, respectively. 4 Due
to the high risk of malignancy in Bosniak IV lesions, an alternative
role in sparing nephrectomy has been hypothesized for the image-
guided percutaneous ablation technique. Image-guided percutaneous
radiofrequency ablation (RFA) has been widely accepted as a
minimally invasive treatment for surgically unresectable renal cell
carcinomas (RCC) with good results in small solid renal tumors where
complete ablation rates ranged from 90% to 100%. 5–8 Following the
same approach, Park et al. proposed image-guided percutaneous RFA
as a valuable alternative for cystic lesions unsuitable for surgery, with
excellent results. 9 Since this approach is applicable to Bosniak IV
lesions, it could be reasonably extended to Bosniak III lesions with a
high risk formalignancy, where surgical excision is often advocated 10
in spite of the possibility that the lesions are found to be benign at
biopsy or surgery. 1–3
Its technical features renderMWA an interesting technology, due to
theminimized thermal dispersion obtained by reducing the “heatsink
effect” as previously reported by Laeseke et al. 11 On this basis, we
hypothesized that MWA would offer better performances for the
treatment of malignant cystic renal lesions, particularly in patients
who should not have undergone nephrectomy for co-morbidities, as
well as for solid RCCs.
In this study we report our preliminary experience with the
efﬁcacy, safety and effectiveness of image-guided percutaneousMWA
in Bosniak category III or IV cystic renal lesions after a 24-month
follow-up period.
2. Methods and materials
Approval for this study was obtained from the local institutional
review board (IRB). Informed consent was waived by the IRB given
the retrospective nature of the study on an anonymized database.
BetweenMay 2008 and Dec 2012, 6 patients (5males, 1 female, mean
1743-9191$ – see front matter © 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
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Fig. 1. (A) An exophytic rounded cystic lesion characterized by (B) an avid contrast enhancement along septa at CEUS examination. (C,D) The same lesion showed no enhancement
at CECT (arrowhead); (D) a ring of fat-stranding due to persisting edema persists at CECT performed 1 month after treatment (arrowhead).
age 74 y, range 60–81) with 7 cystic renal lesions (one Bosniak III and
six Bosniak IV lesions, range 13.8–27mm,mean17.02mm, SD8.5mm)
were treated with percutaneous MWA. 12,13 All patients were judged
not suitable for surgery on the basis of their co-morbidities. Co-
morbidities were distributed as follows: chronic renal failure (n =2);
respiratory and cardiac insufﬁciency (n =2); cancer and abdominal
aortic aneurysm (n=1); amyotrophic lateral sclerosis and solitary
kidney (n =1). To be eligible for the procedure, patients have to meet
the following criteria: Bosniak III or IV lesions no greater than 8 cm in
size, the absence of renal vein thrombosis or extra-renal metastases,
prothrombin time of less than 25 seconds, prothrombin activity
higher than 40%, and a platelet count higher than 40×109 cells/L.
Patients not eligible for surgery or refusing surgery, with an adequate
route for percutaneous access, were eligible for percutaneous thermal
ablation. Before the procedure, the number of cystic lesions, their
size on multiplanar reformatted images (MPR) along the longest
axis and the absence of renal vein thrombosis were evaluated
by performing contrast enhanced ultrasonography (CEUS), as well
as contrast enhanced computed tomography (CECT) or magnetic
resonance imaging (MRI). All patients underwent a detailed pre-
procedural assessment performed by CECT for staging, to evaluate
lesion size, kidney location and proximity of adjacent organs and to
evaluate the possibility of percutaneous access. Lesion locations were
classiﬁed in upper (upper one-third), middle (middle one-third), and
lower (lower one-third) poles based on Gervais et al. 14
During the percutaneousMWA procedure, patients lay in the prone
or semi-prone position. Local anesthesia was performed on the an-
tenna entrance sitewith subcutaneous injection of a 10-ml solution of
2% Mepivacaine. The procedure was performed with anesthesiologic
assistance, under moderate sedation, through I.V. administration of
Propofol (0.5–2.0mg/kg/h, Fresenius SE & Co. KGaA, Bad Homburg,
Germany), Fentanyl (1–2mg/kg, Pﬁzer Pharmaceuticals Group, New
York, USA) and Mydazolam (0.07–0.08mg/kg, Pﬁzer Pharmaceuticals
Group, NewYork, USA). Adequate antibiotic prophylaxiswas achieved
with intravenous administration of 1 g of cefazolin sodium (Ancef,
SmithKline Beecham Pharmaceuticals, Philadelphia, USA) given every
eight hours for three days prior to the procedure, ending two days
post-procedure. During the entire ablation session, patients were
monitored by an anesthesiologist. MWA was performed through a
915MHz microwave generator (Evident™ microwave ablation sys-
tem, Covidien Ltd., USA), connected via coaxial cable to one antenna
that was positioned within the lesion to be ablated. According to
manufacturer’s indications, one antenna was used per each lesion
<3 cm, with a power of 45W set up for ten minutes of total ablation
time in order to obtain an optimal volume of necrosis. The antenna
was continuously perfused with saline solution at room temperature
with a ﬂow rate of 60ml/min to avoid possible thermal damage along
the proximal semi-axis. Each single antenna was removed hot for
the cauterization of the path (target–skin surface). Three procedures
were performed under CT guidance and four under ultrasound (US)
guidance, according to operator expertise. In all cases a CT scan or an
US examination, depending on guidance, was performed to establish
the correct antenna positions before starting treatment.
Immediately after the procedure, a CECT or CEUS was performed
to assess technical success. Every image was reviewed by two
experienced radiologists (G.P.C. and F.F., 20 and 15 years experience
in radiology, respectively). Follow-up imaging with a CECT was
scheduled to take place 1 month after completion of treatment and
at 3, 6 and 12 months for the ﬁrst year; subsequent follow up was
scheduled to take place every 4 months through a CEUS and at
24 months through CECT (Fig. 1).
Grayscale Ultrasound and CEUS were performed using a Philips
iU22 device (Philips, Best, Netherlands). All patients received an in-
travenously administered half-dose (2.5ml) of the second-generation
contrast agent SonoVue© (Bracco, Milan, Italy) followed by the
injection of 10ml of saline solution to homogenize the bolus.
CECTs were carried out by a 64-row scanner (Aquilion 64, Toshiba,
Japan). Each examination was performed in pre-contrast, arterial,
venous and excretory phases, obtained respectively with delays
of 18 s, 70 s and 7 minutes using Sure Start© by the region of
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Fig. 2. Two different lesions observed and treated in the same patient (top and bottom panels). Top panel: (A) antenna entrance site; (B) lesion (asterisk); (C) this lesion appeared as
completely necrotized without contrast enhancement at CECT performed 1month after MWA treatment. Bottom panel: (D,E) the larger lesion appeared necrotized with a “halo” of
fat-stranding 1 month after MWA treatment (arrowhead, E); (F) the “halo” progressively disappeared at CECT 24 months after treatment: a volume reduction of the ablated lesion
was identiﬁed (arrowhead).
Table 1
Deﬁnitions used for study end-points
End-point Deﬁnition
Technical success (TS) Correct positioning of the antenna inside the lesion to be ablated and the subsequent complete ablation checked on CECT/CEUS
performed immediately after the MWA session
Technical effectiveness (TE) Absence of thermo-ablative residues on CECT performed at one month (1st mo) after MWA treatment
Local tumor progression rate (LTPR) Rate of patients in whom thermo-ablative residues are identiﬁed during follow up (beyond 1st mo) in completely ablated lesions
Cancer-speciﬁc survival rate (CSSR) The percentage of patients showing no local tumor progression at the chosen moment of follow up
Overall survival rate (OSR) Global non-speciﬁc survival rate
interest (ROI) positioning technique in abdominal aorta with a
threshold of 100 Hounsﬁeld units (HU). Scans were carried out after
I.V. injection of non-ionic iodinated contrast media (350mg I/mL),
according to patient weight (respectively 85, 115 and 130ml for
60kg, <80kg and 80kg), at a rate of 4.5ml/s followed by
40ml of saline solution at the same ﬂow rate. Complete ablation
of a cystic renal tumor on CECT was deﬁned as the absence of
tumor enhancement with an attenuation value of a difference less
than 10HU when comparing follow-up unenhanced and contrast-
enhanced CT images 9 (Fig. 2). On CEUS, residual non-ablated tissue
was depicted as an irregular peripheral scattered, nodular or eccentric
enhanced area. Non-ablated tumors could be re-treated if MWA
treatment criteria persisted.
Deﬁnitions for the study end-points are reported in Table 1. Tumor
features such as size, location, and HU values for each lesion on each
CECT scan obtained during the arterial phase, and during all follow-up
durations, are reported in Table 2. Ablation time, number of sessions,
total applied energy for all lesions, and respective treatment results
(i.e., the presence or absence of technical success, residual lesion,
and tumor recurrence)were recorded. Complications,major orminor,
when depicted by using US, CEUS, CECT, blood samples or clinical
medical records, were deﬁned according to S.I.R. criteria. 15
3. Results
Seven cystic renal lesions were treated with a total of 7 ablations in
7 sessions (Fig. 3). The ablation time, the number of sessions and
total applied energy for all lesions are as follows: 10min, 1 (single)
session, 45Watt. TS was 100% (7/7); TE was 100% (7/7); LTPR was 0%;
CSSR and OSR were 100%. There were no major complications; minor
complications, resolved before discharging patients, included pain at
needle insertion site, nausea, vomiting and fever.
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Table 2
Lesion sizes before (0) and at 1, 3 and 24mo after MWA session, maximum contrast enhancement (Max CE) reached in each single lesion
among all examinations performed, and location and type of the lesion
Lesion Size (mm)
0 1mo 3mo 24mo
Max CE (HU) Typea
1 24.7 26 24 22 5 Anterior, Lower one-third, right kidney Ex
2 12.7 10 9 8.7 7 Anterior, Upper one-third, right kidney Ex
3 18 19 18.2 16.6 3 Posterior, Upper one-third, left kidney Ex
4 27 28 27.2 25 9 Anterior, Lower one-third, right kidney Ex
5 14 18.6 18.1 17.3 7 Posterior, Upper one-third, right kidney Ex
6 13.8 17.2 15 14.3 4 Posterior, Upper one-third, left kidney Ex
7 21 22.3 22 21 8 Posterior, Upper one-third, right kidney Ex
a Ex, exophytic.
Fig. 3. (A,B) A small rounded exophytic lesion on axial (arrowhead, A) and coronal (arrowhead, B) reformatted CECT images before MWA treatment. (C) The same lesion during the
MWA session: the dotted line shows the planned antenna track, the green circle the antenna entrance site and the violet oval the planned ablation area (diameter 3.7 cm). (D) The
asterisk shows the ablated area on CECT performed immediately after MWA treatment; in particular some air bubbles of vaporization near the ablated site may be observed.
(E,F) CECT performed 1 month (arrow, E) and 24 months (arrow, F) after MWA treatment showing absence of residue/recurrence.
4. Discussion
Surgery, when feasible, is widely accepted 10 as the treatment of
choice for solid tumors; nucleo-resection or spare nephrectomy is
preferred when possible [solitary, small lesions (<4 cm), located
in a peripheral seat]. Ablative techniques have been introduced
with the aim to control the spreading of a local tumor and to
preserve the surrounding parenchyma’s function, with curative or
local control as the primary objectives, when surgery is not feasible.
Different ablation techniques such as radiofrequency ablation (RFA),
cryoablation (CA) or microwave ablation (MWA) have been available
for some time, resulting in few complications, most of which are self-
limited or readily treated, with great advantages if compared with
surgical management. 5–8,16–19
When suspected malignant cystic lesions of the kidney are
considered, such as Bosniak III or IV lesions (malignancy rates 16–
100% and 90–100%), 4 despite the interesting results in solid RCC, the
use of RFA or CA still remains questionable, given that the overall
performances and procedural tips for these treatments are not well
established. Boss et al. 20 reported low effectiveness of RFA for cystic
renal tumors, whilst Park et al. 9 reported optimal results with a
shorter duration of energy application when compared with solid
renal tumors similar in size. The most important limitation of RFA is
the “heatsink effect” with a low efﬁcacy related to a small necrosis
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area caused by undesired RF energy dispersion. This effect is more
evident in highly vascularized tissues or in ﬂuid-ﬁlled, prominent
lesions if large volumes are considered.
To offer an alternative by minimizing this phenomenon, Laeseke
et al. 11 showed the interesting properties ofMWA in a porcinemodel:
this technique appeared less susceptible to perfusion-mediated
cooling, especially in highly perfused tissue, such as kidney tissue,
which is more subject to thermal dispersion. Inspired by this study,
Yu et al. showed that US-guided percutaneous MWA could be
a feasible alternative to obtain a safe and effective approach in
managing RCC 16 due to the minimized thermal dispersion gained by
MWA.
On this basis we hypothesized that MWA could open new
perspectives in approaching suspectedmalignant cystic renal lesions,
acting as a viable alternative when surgery was not feasible. In
our CECT evaluation, based on residual lesion enhancement after
MWA treatment, values ranged from 3HU to 9HU, showing that it
could be acceptable to assume the absence of residual disease and
no recurrences during follow up. These ﬁndings led to optimal results
(shown in Table 3)with the absence ofmajor intra- or peri-procedural
Table 3
Results for study end-points
End-point Result
Technical success (TS) 100%
Technical effectiveness (TE) 100%
Local tumor progression rate (LTPR) 0%
Cancer-speciﬁc survival rate (CSSR) 100%
Overall survival rate (OSR) 100%
complications or recurrences at 24 months. In our opinion, the small
lesion size (<3 cm) may assume a relevance in our results: it was
one of the most important criteria to reach a complete ablation with
high technical success rate and improved clinical efﬁcacy. It acted
by enforcing synergistic effects obtained by linking the minimized
“heatsink effect”, formerly reported as extremelyminimized inMWA,
and the small volume of ﬂuid-ﬁlled content, both factors that could
determine thermal dispersion in RFA-treated cystic lesions. 9
A questionable point in our series was the lack of a histological
diagnosis before MWA treatment. Some studies reported that a
biopsy of renal mass could be useful in evaluating the Bosniak
II or III cystic renal mass 1,2 whilst other studies reported that the
biopsy could be unreliable, particularly in pathologically diagnosing
cystic masses. 13,21,22 Considering the lesions treated in our series,
all classiﬁed as Bosniak category III/IV on the basis of imaging,
surgery would have been considered in all cases (positive or negative
histological presence of malignant cells). If the biopsy specimen was
positive for malignancy, this result merely conﬁrmed the need for
surgery, whereas on the other hand, a negative test for malignancy
did not impact the decision for surgery, not excluding the possibility of
a sampling error or a potential future degeneration.Moreover, in some
cystic RCCs where cystic architecture dominates the morphological
appearance of the tumors, an adequate sample of malignant cells was
not always available for a conclusive histological assessment, making
biopsy not useful. 23 Previous studies reported that biopsy was not
performed in two cystic renal masses despite RFA treatment and that
there was a repeated negative biopsy for malignancy in a complex
cystic–solid renal mass. 8,14 According to literature in our series, a
careful CECT evaluation allowed the diagnosis of Bosniak III/IV lesions,
avoiding invasive management. Moreover, the absence of contrast
enhancement inside the ablated lesion after treatment was judged
as a sufﬁcient sign of absence of viable tissue persistence, especially
considering the disease-free survival at 24 months in all cases.
A technical note regards percutaneous MWA guidance; in our
experience the choice of image-guiding during renal ablation was
strictly related to operator expertise and lesion features. Ultrasound
has great advantages in the capability of real-time monitoring and
its lack of ionizing radiation. However, being operator-dependent, it
was compromised in certain settings, for example, in patients with a
large body habitus, in the presence of abundant bowel gas, or when
the tumor is near bowel. Moreover, US drawbacks are linked to the
hyperechoic bubbles produced by vaporization during the procedure
that could impact image quality. On the other hand, CT was typically
associated with fewer changes in the imaging pattern of ablated
renal masses, although intratumoral hyperdensity and gas generated
during ablation sometimes could limit visualization. 24
Only minor complications were observed in our patients, in
particular pain at needle insertion site, vomiting or fever; this
symptomatology was judged tolerable by patients. Therefore the
procedure may be considered acceptable and safe, especially if
compared with a surgical approach.
Limitations of the study are the retrospective evaluation; the
selection bias based on type of lesion; and the small cohort of
patients that included only small malignant cystic renal lesions
(less than 4 cm in diameter). The last limitation was strictly linked
to the strength of inclusion in patient selection, hypothesizing an
MWA approach only when a clear beneﬁt for the patient is expected
after following a decision-making process well established with
referent nephrologists.
In summary, our preliminary experiencewithMWA, notwithstand-
ing the small number of cases and the need for further investigation,
deﬁnes a potential role for US/CT-guided percutaneous MWA in
treating Bosniak category III or IV cystic renal lesions, resulting in
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